PL359327A1 - Kompozycje zawierające blokery transferu L-Dopa zkomórek nerkowych do leczenia choroby Parkinsona - Google Patents

Kompozycje zawierające blokery transferu L-Dopa zkomórek nerkowych do leczenia choroby Parkinsona

Info

Publication number
PL359327A1
PL359327A1 PL01359327A PL35932701A PL359327A1 PL 359327 A1 PL359327 A1 PL 359327A1 PL 01359327 A PL01359327 A PL 01359327A PL 35932701 A PL35932701 A PL 35932701A PL 359327 A1 PL359327 A1 PL 359327A1
Authority
PL
Poland
Prior art keywords
dopa
renal cell
parkinson
treatment
disease
Prior art date
Application number
PL01359327A
Other languages
English (en)
Inventor
Patricio Soares-Da-Silva
Original Assignee
Portela & Companhia S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portela & Companhia S.A. filed Critical Portela & Companhia S.A.
Publication of PL359327A1 publication Critical patent/PL359327A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL01359327A 2000-03-14 2001-03-13 Kompozycje zawierające blokery transferu L-Dopa zkomórek nerkowych do leczenia choroby Parkinsona PL359327A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0006063A GB2348371B (en) 2000-03-14 2000-03-14 Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
PCT/EP2001/002896 WO2001068065A2 (en) 2000-03-14 2001-03-13 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
PL359327A1 true PL359327A1 (pl) 2004-08-23

Family

ID=9887552

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01359327A PL359327A1 (pl) 2000-03-14 2001-03-13 Kompozycje zawierające blokery transferu L-Dopa zkomórek nerkowych do leczenia choroby Parkinsona

Country Status (23)

Country Link
US (1) US20040242503A1 (pl)
EP (1) EP1267853B1 (pl)
JP (1) JP3677002B2 (pl)
KR (1) KR100738746B1 (pl)
CN (1) CN1262269C (pl)
AR (1) AR035567A1 (pl)
AT (1) ATE275397T1 (pl)
AU (1) AU781280B2 (pl)
BR (1) BR0109220A (pl)
CA (1) CA2402712C (pl)
CZ (1) CZ297123B6 (pl)
DE (1) DE60105401T2 (pl)
DK (1) DK1267853T3 (pl)
ES (1) ES2228858T3 (pl)
GB (1) GB2348371B (pl)
HU (1) HUP0300130A3 (pl)
MX (1) MXPA02009043A (pl)
PL (1) PL359327A1 (pl)
PT (1) PT1267853E (pl)
RU (1) RU2266111C2 (pl)
SI (1) SI1267853T1 (pl)
TR (1) TR200402661T4 (pl)
WO (1) WO2001068065A2 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
US7381772B2 (en) * 2003-12-12 2008-06-03 E. I. Du Pont De Nemours And Company Toughened poly(lactic acid) compositions
PT1751087E (pt) 2004-06-04 2012-09-10 Xenoport Inc Derivados de levodopa e as suas composições e utilizações
WO2006004552A1 (en) * 2004-07-07 2006-01-12 Kampavata Ab Transgenic non-human animal for use in research models for studying parkinson's disease
US8017649B2 (en) * 2005-03-11 2011-09-13 Howard Florey Institute Of Experimental Physiology And Medicine Flavonoid compounds and uses thereof
GB0505756D0 (en) * 2005-03-21 2005-04-27 Mars Uk Ltd Method
WO2007034024A2 (en) * 2005-09-21 2007-03-29 Orion Corporation Treatment of symptoms of parkinson' s disease
AU2006339607A1 (en) * 2005-12-02 2007-09-13 Sirtris Pharmaceuticals, Inc. Modulators of Cdc2-like kinases (Clks) and methods of use thereof
US7563821B2 (en) 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
CA2673336A1 (en) 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
WO2008079387A1 (en) 2006-12-21 2008-07-03 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
RU2009134137A (ru) * 2007-02-14 2011-03-27 Марс, Инкорпорейтед (Us) Нейрогенные соединения
BRPI0801239A2 (pt) * 2008-04-01 2009-11-17 Ache Lab Farmaceuticos Sa uso de um ou mais benzopiranonas, composição farmacêutica e método de prevenção ou tratamento de doenças, disfunções e distúrbios associados a monoamino oxidase
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
US9290445B2 (en) 2008-10-20 2016-03-22 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
US20100158829A1 (en) * 2008-12-24 2010-06-24 Conopco, Inc., D/B/A Unilever Method and Composition for Color Modulation
CN101856350A (zh) * 2009-04-13 2010-10-13 中国医学科学院药物研究所 黄芩素在制备预防和治疗帕金森病药物中的应用
WO2011056240A2 (en) 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
CN101797243B (zh) * 2010-03-23 2012-01-18 广东药学院 一种含有左旋多巴和冰片的组合物及其应用
KR101327936B1 (ko) * 2011-07-06 2013-11-13 한국식품연구원 옥시레스베라트롤 이민 유도체를 유효성분으로 함유하는 뇌신경보호 효과를 가지는 조성물
CN102755312A (zh) * 2012-07-16 2012-10-31 中国科学院大连化学物理研究所 具有黄酮骨架结构的化合物作为帕金森症治疗药物的应用
GB201302755D0 (en) 2013-02-15 2013-04-03 Mars Inc Horse supplement
CN103211832A (zh) * 2013-04-24 2013-07-24 无锡艾德美特生物科技有限公司 含杨酶苷或/和杨梅素的药物组合物及其在制备帕金森治疗药物中的用途
CN104116730A (zh) * 2013-04-26 2014-10-29 中国科学院大连化学物理研究所 二氢杨梅素作为活性成份在制备帕金森症治疗药物中的应用
KR101583399B1 (ko) * 2013-10-22 2016-01-08 충북대학교 산학협력단 아사리닌 또는 (-)-세사민을 함유하는 파킨슨병 예방 또는 치료용 약학조성물
EP3275433A1 (en) * 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
KR102681552B1 (ko) * 2016-09-27 2024-07-04 (주)아모레퍼시픽 소장 상피세포에서의 카테킨 흡수 증진제
CN111329853A (zh) * 2020-04-21 2020-06-26 遵义医科大学 一种治疗帕金森病的药物组合物及其应用和治疗帕金森病的药物
CN116908319A (zh) * 2023-05-31 2023-10-20 苏州和合医学检验有限公司 一种检测血液中苄丝肼浓度的方法
CN119192117B (zh) * 2024-10-31 2025-09-26 贵州医科大学 一种从马尾松松塔内分离出的黄酮类化合物及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190672A (en) * 1978-09-01 1980-02-26 Stanley Fahn Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone
JPS5852219A (ja) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd パ−キンソン病治療剤
JPS6450877A (en) * 1987-08-20 1989-02-27 Ichimaru Pharcos Inc Oxygen radical catching and removing agent
JPH035423A (ja) * 1989-06-01 1991-01-11 Ichimaru Pharcos Co Ltd フラボノイド含有過酸化脂質生成抑制剤
US5702752A (en) * 1996-03-13 1997-12-30 Archer Daniels Midland Company Production of isoflavone enriched fractions from soy protein extracts
JPH09241637A (ja) * 1996-03-14 1997-09-16 Chugai Pharmaceut Co Ltd 活性酸素ラジカル除去用組成物およびその方法
GB9702310D0 (en) * 1997-02-05 1997-03-26 Univ Hertfordshire Invention
EP1032403B1 (en) * 1997-10-24 2012-05-02 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
JPH11323326A (ja) * 1998-02-06 1999-11-26 Nagaoka Koryo Kk 活性酸素消去剤、皮膚保全剤および変色防止剤
FR2787319B1 (fr) * 1998-12-22 2002-06-14 Oreal Utilisation d'hydroxystilbenes pour la teinture, composition prete a l'emploi les contenant et procede de teinture
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
KR101098209B1 (ko) * 2002-01-28 2011-12-23 교와 핫꼬 기린 가부시키가이샤 운동성 질환에 걸린 환자의 치료 방법

Also Published As

Publication number Publication date
AU5828301A (en) 2001-09-24
US20040242503A1 (en) 2004-12-02
ATE275397T1 (de) 2004-09-15
GB2348371A (en) 2000-10-04
WO2001068065A2 (en) 2001-09-20
GB2348371B (en) 2001-04-04
HUP0300130A2 (en) 2003-05-28
KR20030095184A (ko) 2003-12-18
AU781280B2 (en) 2005-05-12
SI1267853T1 (en) 2005-04-30
DE60105401D1 (de) 2004-10-14
CZ20023348A3 (cs) 2003-02-12
EP1267853A2 (en) 2003-01-02
EP1267853B1 (en) 2004-09-08
PT1267853E (pt) 2004-12-31
HUP0300130A3 (en) 2005-11-28
CN1262269C (zh) 2006-07-05
WO2001068065A3 (en) 2002-02-21
CN1429109A (zh) 2003-07-09
DE60105401T2 (de) 2005-10-13
RU2266111C2 (ru) 2005-12-20
DK1267853T3 (da) 2005-01-10
GB0006063D0 (en) 2000-05-03
WO2001068065A9 (en) 2002-07-18
JP3677002B2 (ja) 2005-07-27
BR0109220A (pt) 2003-03-18
ES2228858T3 (es) 2005-04-16
CZ297123B6 (cs) 2006-09-13
CA2402712C (en) 2005-05-17
KR100738746B1 (ko) 2007-07-12
JP2003526658A (ja) 2003-09-09
CA2402712A1 (en) 2001-09-20
TR200402661T4 (tr) 2004-11-22
AR035567A1 (es) 2004-06-16
MXPA02009043A (es) 2004-08-19

Similar Documents

Publication Publication Date Title
GB2348371B (en) Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
DK0841904T3 (da) Orale farmaceutiske præparater med forsinket frigivelse af reversible protonpumpeinhibitorer
DK1213015T3 (da) Oralt farmaceutisk præparat med forsinket frigivelse af protonpumpeinhibitorer
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
DK1185253T3 (da) Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac
NO20101070L (no) Fremgangsmate til dosering av et medikament, samt doseringsform
WO2005045055A3 (en) The use of plp with peg-rmetase in vivo for enhanced efficacy
BRPI0412364A (pt) composição farmacêutica sólida, compreendendo amisulpride
WO2001030331A3 (en) Therapeutic compositions including protein kinase c inhibitors
WO2000001415A3 (en) Use of inhibitors of protein kinase c epsilon to treat pain
PT1441708E (pt) Composições e métodos para aumentar a observância de terapias utilizando inibidores da aldeído desidrogenase e para tratar alcoolismo
WO2006037061A3 (en) Compositions and methods of using d-dopa to treat parkinson's disease
WO2005030700A3 (en) Amino acids with affinity for the alpha2delta-protein
PL377584A1 (pl) Deuterowane pochodne katecholoaminy oraz środki lecznicze zawierające te związki
NZ523606A (en) Pharmaceutical compositions and methods for use
WO2001054707A3 (de) Veränderung von oberflächenproteomem durch aminopeptidase-inhibitoren
WO2002053097A3 (en) Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
NZ336043A (en) Use of COMT inhibitors for preventing diabetic vascular dysfunctions or neuropathy
AU2003251522A1 (en) Mutant plant caffeic acid/5-hydroxyferulic acid 3/5-0-methyltransferases (comt), methods for preparation and use thereof
DK1330428T3 (da) Faste præparater til oral administration indeholdende ikke-hygroskopiske salte af L-carnitin og alkanoyl-L-carnitiner med taurinchlorid
AU3903701A (en) Diclofenac pharmaceutical composition based on vitamin-e, papain and hyaluronidase
ATE334982T1 (de) 7-chlor-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-
WO2002068389A3 (de) Indolderivate mit inhibitorischer wirkung auf phenoloxidasen
WO2004006937A3 (fr) Compositions pharmaceutiques a base d'inhibiteurs de la 5-alpha-reductase et leurs utilisations

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)